BioCardia (NASDAQ: BCDA) furnishes Q3 2025 earnings press release in 8-K

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

BioCardia, Inc. filed a current report to furnish its latest quarterly results update. On November 12, 2025, the company issued a press release announcing its financial results for the quarter ended September 30, 2025, and attached that release as an exhibit.

The press release is provided as Exhibit 99.1 and is treated as "furnished" rather than "filed" under securities law, which limits certain legal liabilities and incorporation by reference into other SEC documents unless specifically cited.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

11/12/2025 - 04:10 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

BIOCARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38999		23-2753988
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

320 Soquel Way Sunnyvale, California 94085
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (650) 226-0120

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	BCDA	The Nasdaq Capital Market
Warrant to Purchase Common Stock	BCDAW	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 12, 2025, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		BioCardia, Inc. press release dated November 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCARDIA, INC.

/s/ Peter Altman, Ph.D.
Peter Altman, Ph.D.
President and Chief Executive Officer

Date: November 12, 2025

Source: View Original Filing on SEC EDGAR

FAQ

What did BioCardia (BCDA) disclose in this November 12, 2025 8-K?

BioCardia disclosed that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company attached this earnings press release as Exhibit 99.1, furnishing it under Item 2.02 on results of operations and financial condition.

Which period’s results does BioCardia’s November 12, 2025 press release cover?

The press release furnished by BioCardia on November 12, 2025 covers financial results for the quarter ended September 30, 2025. Investors must review Exhibit 99.1 to see the specific revenue, loss, cash, or other detailed performance figures for that quarter.

Is BioCardia’s earnings press release in this 8-K considered filed or furnished?

BioCardia states the earnings press release and related Item 2.02 information are furnished, not filed, for purposes of Section 18 of the Exchange Act. This treatment limits certain liabilities and incorporation into other SEC filings unless expressly referenced later.

Where can investors find the detailed quarterly financial results for BioCardia (BCDA)?

Investors can find BioCardia’s detailed quarterly financial results in Exhibit 99.1 to this report. That exhibit is the full press release issued on November 12, 2025, which contains the specific financial metrics and narrative discussion for the quarter.

Who signed BioCardia’s November 12, 2025 8-K on behalf of the company?

The 8-K was signed on behalf of BioCardia by Peter Altman, Ph.D., who serves as President and Chief Executive Officer. His electronic signature appears in the signature block dated November 12, 2025, evidencing company authorization for the furnished information.

What exhibits are included with BioCardia’s November 12, 2025 8-K filing?

The filing includes Exhibit 99.1, which is BioCardia’s press release dated November 12, 2025, announcing quarterly financial results. It also lists Exhibit 104, the cover page interactive data file embedded within the Inline XBRL version of the current report.